Pharmacogenetics in mental health
Research type
Research Study
Full title
Personalised medicine for psychotropic drugs (antipsychotics, antidepressants, antimanic agents and other pychotropics)
IRAS ID
193707
Contact name
Elvira Bramon
Contact email
Sponsor organisation
University College London
Clinicaltrials.gov Identifier
Z6364106, UCL Data Protection Number
Duration of Study in the UK
6 years, 0 months, 1 days
Research summary
Schizophrenia and bipolar disorder constitute one of the leading causes of disability in young adults. Depression is a highly common condition affecting about one in four people. Antipsychotics and antidepressants are the most common treatment for these illnesses. Although they are effective for many patients they can also cause severe side effects. As a result of this patient adherence is low.
It is possible that genetic differences could explain why some patients respond to their treatment better than others and also why some patients experience severe side effects. By running this study, we seek to investigate if genetic profiling can help optimise the prescribing of psychotropic medications and lead to improved clinical outcomes and reduced side effects.
Participants who consent to take part in the study will be offered a genetic test. We will recruit adult patients with schizophrenia, delusional, schizoaffective or bipolar disorders. The initial assessment will take place on the hospital ward or at a community centre if the participant is an outpatient. The follow-up assessment can take place on the ward or in the community if the patient has been discharged. The final follow-up will be undertaken based on clinical records.
REC name
London - Camden & Kings Cross Research Ethics Committee
REC reference
19/LO/1403
Date of REC Opinion
28 Oct 2019
REC opinion
Further Information Favourable Opinion